Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of allogeneic adipose-derived mesenchymal stem cells for cicatricial conjunctivitis with ocular involvement
2021-005486-40Phase 2Active
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Start
- Feb 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic adipose tissue-derived mesenchymal stem cells in Cicatricial conjunctivitis, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and 1 more, sponsored by Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz. Primary endpoints: Safety and tolerability and Feasibility. Started Feb 2022; status: active.
02
Drugs
allogeneic adipose tissue-derived mesenchymal stem cells
03
Conditions
Cicatricial conjunctivitisStevens-Johnson syndrome (SJS)toxic epidermal necrolysis (TEN)cicatricial pemphigoid (CP)
Beyond the preview
Go deeper on 2021-005486-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005486-40.